Tyrosine kinases: a target of epigenetic influences and a new direction in the treatment of multiple sclerosis

Boyko A.N.

doi:https://doi.org/10.17116/jnevro202212207227

Boyko A.N.

Pirogov National Research Medical University;
Federal Center for Brain Research and Neurotechnologies

SPIN RSCI: 9921-9109
Scopus AuthorID: 7102247663
ORCID: 0000-0002-2975-4151

Tyrosine kinases: a target of epigenetic influences and a new direction in the treatment of multiple sclerosis

Authors:

Boyko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7‑2): 27‑30

DOI: 10.17116/jnevro202212207227

Read: 3865 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Boyko AN. Tyrosine kinases: a target of epigenetic influences and a new direction in the treatment of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7‑2):27‑30. (In Russ.)
https://doi.org/10.17116/jnevro202212207227

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Molecular mechanisms of acute disseminated encephalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11

The role of monocytes in the immunopathogenesis of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27

Results of a 5-year project for the early diagnosis of multiple sclerosis in first-line blood relatives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33

Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple sclerosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38

Features of the clinical course of multiple sclerosis as a factor in persistent disability. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44

Quantitative analysis of cerebrospinal fluid flow in multiple sclerosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):45-50

Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):51-59

Study of neurodegeneration in multiple sclerosis using optical coherence tomography of the retina and magnetic resonance morphometry of the brain. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):66-72

Evaluation of the effect of highly effective multiple sclerosis disease-modifying drugs on the progression of the disease using diffusion-weighted magnetic resonance imaging with tractography. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):73-78

Evaluation of the effectiveness of intensive medical rehabilitation in MS patients through the prism of functional tests and serum neurofilaments. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):79-83

Abstract:

Studies have shown that tyrosine kinases can be important in the pathogenesis of multiple sclerosis (MS) through the regulatory network of microRNAs. A microRNA network-based analysis revealed 17 receptor pathways activated by tyrosine kinase and regulated by microRNAs encoded at the DLK1-DIO3 locus on chromosome 14. Tyrosine kinases are actively involved in the epigenetic regulation of the pathological process in MS with the participation of a microRNA network and thus attract attention as a target for the development of new ways for the treatment of MS. The greatest attention was attracted by Bruton tyrosine kinase inhibitors (TKBi), which showed their ability to suppress the activity of autoimmune inflammatory lesions in the MS model — experimental autoimmune encephalomyelitis (EAE). This is due to the influence of TRB on the activity of B cells, which have a critical role in the development of the pathological process. The review discusses the types of TRBi, the features of their action in EAE and the results of the first studies in MS.

Keywords:

multiple sclerosis

microRNAs

tyrosine kinases

Bruton tyrosine kinase

treatment

Authors:

Boyko A.N.

Pirogov National Research Medical University;
Federal Center for Brain Research and Neurotechnologies

SPIN RSCI: 9921-9109
Scopus AuthorID: 7102247663
ORCID: 0000-0002-2975-4151

Received:

10.05.2022

Accepted:

02.06.2022

Close metadata

References:

Gusev EI, Boyko AN. Multiple sclerosis. Scientific-practical recommendations. ROOI «Zdorobie tcheloveka». 2020;608. (In Russ.).
Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I & II: Ann Neurol. 2007;61:288-299, 504-513. https://doi.org/10.1002/ana.21141
Patsopoulos NA, Baranzini SE, Santaniello A, et al. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;80:365. https://doi.org/10.1126/science.aav7188
Lawson HA, Cheverud JM, Wolf JB. Genomic imprinting and parent-of-origin effects on complex traits. Nat Rev Genet. 2013;14:609-617. https://doi.org/10.1038/nrg3543
Baulina AN, Kulakova OI, Kiselev IN, et al. Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission. J Neuroimmunol. 2018;317:67-76. https://doi.org/10.1016/j.jneuroim.2018.01.005
Baulina AN, Osmak GA, Kiselev IN, et al. MiRNAs from DLK1-DIO3 Imprinted Locus at 14q32 are Associated with Multiple Sclerosis: Gender-Specific Expression and Regulation of Receptor Tyrosine Kinases Signaling. Cells. 2019;8(2):133-140. https://doi.org/10.3390/cells8020133
Huynh JL, Casaccia P. Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment. Lancet Neurol. 2013;12(2):195-206. https://doi.org/10.1016/S1474-4422(12)70309-5
Comi G, Bar-Or A, Lassmann H, et al. Expert Panel of the 27th Annual Meeting of the European Charcot Foundation Role of B Cells in Multiple Sclerosis and Related Disorders. Ann Neurol. 2021;89:13-23. https://doi.org/10.1002/ana.25927
Melnikov MV, Rogovsky VS, et al. Mechanisms of participation of B-lymphocytes in the pathogenesis of multiple sclerosis. Medicina Extremalnoi Situatzii. 2021;2:34-39. (In Russ.). https://doi.org/10.47183/mes.2021.020
Torke S, Weber MS. Inhibition of Bruton´s tyrosinekinase as a novel therapeutic approach in multiple sclerosis. Expert Opin Investig Drugs. 2020;29(10):1143-1150. https://doi.org/10.1080/13543784.2020.1807934
Pan Z, Scheerens H, Li SJ, et al. Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase. Chem Med Chem. 2007;2:58-61. https://doi.org/10.1002/cmdc.200600221
Zheng J, Wu J, Ding X, et al. Small Molecule Approaches to Treat Autoimmune and Inflammatory Diseases (Part I): Kinase Inhibitors. Bioorg Med Chem Lett. 2021;38:127862. https://doi.org/10.1016/j.bmcl.2021.127862
Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s Tyrosine Kinase in B Cell Malignancies. Nat Rev Cancer. 2014;14:219-232. https://doi.org/10.1038/nrc3702
Liang C, Tian D, Ren X, et al. The Development of Bruton’s Tyrosine Kinase (BTK) Inhibitors from 2012 to 2017: A Mini-Review. Eur J Med Chem. 2018;151:315-326. https://doi.org/10.1016/j.ejmech.2018.03.062
Estupiñán HY, Berglöf A, Zain R, Smith C.E. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Front. Cell Dev Biol. 2021;9:630942. https://doi.org/10.3389/fcell.2021.630942
Liu Q, Sabnis Y, Zhao Z, et al. Developing Irreversible Inhibitors of the Protein Kinase Cysteinome. vChem. Biol. 2013;20:146-159. https://doi.org/10.1016/j.chembiol.2012.12.006
Gu D, Tang H, Wu J, et al. Targeting Bruton Tyrosine Kinase Using Non-Covalent Inhibitors in B Cell Malignancies. J Hematol Oncol. 2021;14:40. https://doi.org/10.1186/s13045-021-01049-7
Crespo O, Kang SC, Daneman R, et al. Tyrosine Kinase Inhibitors Ameliorate Autoimmune Encephalomyelitis in a Mouse Model of Multiple Sclerosis. J Clin Immunol. 2011;31:1010-1020. https://doi.org/10.1007/s10875-011-9579-6
Menzfeld C, John M, van Rossum D, et al. Tyrphostin AG126 Exerts Neuroprotection in CNS Inflammation by a Dual Mechanism: AG126 in Autoimmunity and Inflammation. Glia. 2015;63:1083-1099. https://doi.org/10.1002/glia.22803
Torke S, Pretzsch R, Häusler D, et al. Inhibition of Bruton’s Tyrosine Kinase Interferes with Pathogenic B-Cell Development in Inflammatory CNS Demyelinating Disease. Acta Neuropathol. 2020;140:535-548. https://doi.org/10.1007/s00401-020-02204-z
Syed S, Yonkers N, LaGanke C, et al. Efficacy and Safety of Tolebrutinib in Patients with Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study. Neurology. 2021;96(S15):2260.
García-Merino A. Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy. Cells. 2021;10(10):2560. https://doi.org/10.3390/cells10102560
Crawford JJ, Johnson AR, Misner DL, et al. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development. J Med Chem. 2018;61:2227-2245. https://doi.org/10.1021/acs.jmedchem.7b01712
Montalban X, Arnold DL, Weber MS, et al. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. N Engl J Med. 2019;380:2406-2417. https://doi.org/10.1056/NEJMoa1901981
Dhillon S. Orelabrutinib: First Approval. Drugs. 2021;81:503-507. https://doi.org/10.1007/s40265-021-01482-5
Crofford LJ, Nyhoff LE, Sheehan JH, et al. The Role of Bruton’s Tyrosine Kinase in Autoimmunity and Implications for Therapy. Expert Rev Clin Immunol. 2016;12:763-773. https://doi.org/10.1586/1744666X.2016.1152888
Steinmaurer A, Wimmer I, Berger T, et al. Bruton’s Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis. Curr Pharm Des. 2022;28(6):437-444. https://doi.org/10.2174/1381612827666210701152934